Mink Therapeutics Inc. and Autonomous Therapeutics Inc. have announced a research collaboration aimed at targeting and treating metastatic tumors.

Researchers from University of Science and Technology of China (USTC) published data for a novel multivalent mRNA mpox vaccine candidate, MPXV-1103.

Bayer AG and Moma Therapeutics Inc. have entered into a collaboration, under an option and exclusive license agreement, to develop and commercialize a small-molecule oncology program.

Antag Therapeutics ApS has received IND clearance from the FDA for lead molecule, AT-7687. A phase I trial will evaluate AT-7687 in healthy lean and healthy obese subjects, including as monotherapy and in combination with semaglutide in the healthy obese individuals.

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a cell surface molecule with immunosuppressive function involved in T-cell immune regulation and proliferation. Researchers from Shanghai Junshi Biosciences Co. Ltd. and collaborators described the preclinical evaluation of JS-007, a humanized monoclonal antibody targeting CTLA-4, in cancer models.